CAJ | 학술논문

目的：观察卡培他滨联用奥沙利铂（ XELOX方案）与奥沙利铂联合替吉奥（ SOX方案）治疗进展期胃癌的临床疗效和安全性，为进展期胃癌治疗方案的选择提供参考。方法以120例接受XELOX方案治疗的进展期胃癌患者为XELOX组，以120例接受SOX方案治疗的患者为SOX组。观察其疗程结束后临床疗效及毒副反应发生情况。结果 XELOX组有效率为51.7%，SOX组为48.3%，比较差异无统计学意义（P跃0.05）。2组患者主要毒副反应均为外周神经毒性、粒细胞减少、恶心呕吐，毒副反应发生率2组比较差异无统计学意义（ P 均跃0.05）。末次随访 XELOX 组患者存活11例（9.2%），SOX 组存活13例（10.8%），2组患者末次随访存活率比较差异无统计学意义（ P均跃0.05）。XELOX组与SOX组疾病无进展生存期及生存期比较差异无统计学意义（ P均跃0.05）。结论 XELOX方案与SOX方案疗效相当，2种方案引发的毒副反应在患者可耐受范围内，均可作为进展期胃癌的首选治疗方案。
목적：관찰잡배타빈련용오사리박（ XELOX방안）여오사리박연합체길오（ SOX방안）치료진전기위암적림상료효화안전성，위진전기위암치료방안적선택제공삼고。방법이120례접수XELOX방안치료적진전기위암환자위XELOX조，이120례접수SOX방안치료적환자위SOX조。관찰기료정결속후림상료효급독부반응발생정황。결과 XELOX조유효솔위51.7%，SOX조위48.3%，비교차이무통계학의의（P약0.05）。2조환자주요독부반응균위외주신경독성、립세포감소、악심구토，독부반응발생솔2조비교차이무통계학의의（ P 균약0.05）。말차수방 XELOX 조환자존활11례（9.2%），SOX 조존활13례（10.8%），2조환자말차수방존활솔비교차이무통계학의의（ P균약0.05）。XELOX조여SOX조질병무진전생존기급생존기비교차이무통계학의의（ P균약0.05）。결론 XELOX방안여SOX방안료효상당，2충방안인발적독부반응재환자가내수범위내，균가작위진전기위암적수선치료방안。
Objective To study the comparison about clinical effect and safety between capecitabine combined with oxaliplatin and oxaliplatin combinbed with S-1 in the treatment of advanced gastric cancer,and to provide a ref-erence for the treatment of advanced gastric cancer. Methods The 120 patients of the XELOX group were treated with XELOX regimen,while 120 patients of the SOX group were treated with SOX regimen. After the treatment,the clinical effect and the incidence of toxicities were compared between the two groups. Results The response rate of the XELOX group and the SOX group were 51. 7% and 48. 3%,the difference between the two groups had no statis-tical significance(P<0. 05). The main toxicities of the two groups were peripheral neurotoxicity,neutropenia,nau-sea and vomiting,and there was no statistical significant difference in the incidence of toxicities between the two groups(P>0. 05). The survival of the two groups was 11 patinets(9. 2%)and 13 patients(10. 8%)in the last follow-up,the difference had no statistical significance(P>0. 05). The progression-free survival and overall sur-vival of the two groups had no statistical difference(P>0. 05). Conclusion The clinical effect of XELOX regimen was equal with SOX regimen for advanced gastric cancer,and the toxicities in the tolerable range of patients,the two regimens could be used as the first choice for advanced gastric cancer.